Home › Research › Health systems and care delivery
Advances in the drug treatment of Alzheimer's disease: pathophysiology and mechanisms of action
Nowell Joseph, Crook Harry, de Leon Mony J, Edison Paul. BMJ (Clinical research ed.), 2026-04-21
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimer's disease, the leading cause of dementia, is a multifactorial disorder involving amyloid beta (Aβ) and tau deposition, impaired glucose metabolism, neuroinflammation, mitochondrial dysfunction, insulin resistance, and progressive brain atrophy. Anti-Aβ therapies have shown clinical efficacy and are licensed in several countries. Amyloid related imaging abnormalities remain a key safety concern, and reimbursement varies across healthcare systems. The mechanisms underlying continued cognitive decline after Aβ clearance remain unclear and might be independent of amyloid pathology. Because Alzheimer's disease involves multiple pathological processes, effective management will likely require combination treatments addressing tau aggregation, neuroinflammation, synaptic loss, and metabolic dysfunction. Numerous compounds targeting these mechanisms are currently in late stage development for both early and advanced disease. These emerging approaches represent a shift toward multimodal, disease modifying strategies designed to improve patient outcomes and quality of life. Here, we review recent therapeutic advances in Alzheimer's disease and provide perspectives on novel treatment strategies.
What this study adds
Evidence grade: Low
This review notes that anti-amyloid therapies have shown clinical efficacy and are licensed in several countries, but that the mechanisms behind continued decline after amyloid clearance remain unclear and may be independent of amyloid pathology. It argues that effective management will likely require combination treatments targeting tau, neuroinflammation, synaptic loss and metabolic dysfunction, many still in late-stage development.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Joseph, N., Harry, C., de Leon Mony, J., & Paul, E. (2026). Advances in the drug treatment of Alzheimer's disease: pathophysiology and mechanisms of action. BMJ (Clinical research ed.). https://doi.org/10.1136/bmj-2023-078881
Vancouver
Joseph N, Harry C, de Leon Mony J, Paul E. Advances in the drug treatment of Alzheimer's disease: pathophysiology and mechanisms of action. BMJ (Clinical research ed.). 2026. doi:10.1136/bmj-2023-078881. PMID: 42011967.
BibTeX
@article{joseph2026-42011967,
author = {Joseph, Nowell and Harry, Crook and de Leon Mony, J. and Paul, Edison},
title = {{Advances in the drug treatment of Alzheimer's disease: pathophysiology and mechanisms of action}},
journal = {BMJ (Clinical research ed.)},
year = {2026},
doi = {10.1136/bmj-2023-078881},
pmid = {42011967},
url = {https://doi.org/10.1136/bmj-2023-078881}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The mechanisms underlying continued cognitive decline after Aβ clearance remain unclear and might be independent of amyloid pathology.
- Because Alzheimer's disease involves multiple pathological processes, effective management will likely require combination treatments addressing tau aggregation, neuroinflammation, synaptic loss, and metabolic dysfunction.
- Numerous compounds targeting these mechanisms are currently in late stage development for both early and advanced disease.
- These emerging approaches represent a shift toward multimodal, disease modifying strategies designed to improve patient outcomes and quality of life.
- Here, we review recent therapeutic advances in Alzheimer's disease and provide perspectives on novel treatment strategies.
Why it matters
This review notes that anti-amyloid therapies have shown clinical efficacy and are licensed in several countries, but that the mechanisms behind continued decline after amyloid clearance remain unclear and may be independent of amyloid pathology. It argues that effective management will likely require combination treatments targeting tau, neuroinflammation, synaptic loss and metabolic dysfunction, many still in late-stage development.
Study details
- Evidence strengthLow
How this study scored 43/100
Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (BMJ (Clinical research ed.)) |
| Journal's citation record | 3 / 4 | BMJ: journal h-index 413 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 3 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.5 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 4 / 6 | Cited 12.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Paul Edison: h-index 53 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Imperial College London: institution h-index 1,744 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42011967) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 43 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 49.
Related studies in Health systems and care delivery from nearby years
Also in Health systems and care delivery
172 studies in the library are filed under Health systems and care delivery with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Health systems and care delivery hub.